Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Vij

Showing results (41-50 of 56) with videos related to

Pageof 6
Sort By:
Transplant Infectious Disease : an Official Journal of the Transplantation Society|November 19, 2011
Oral valganciclovir versus ganciclovir as delayed pre-emptive therapy for patients after allogeneic hematopoietic stem cell transplant: a pilot trial (04-0274) and review of the literatureJ S Chawla, A Ghobadi, J Mosley, et al.
Bone Marrow Transplantation|July 5, 2001
Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulinH Khoury, A Kashyap, D R Adkins, et al.
Leukemia|April 26, 2018
Baricitinib-induced blockade of interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft-versus-host diseaseJaebok Choi, Matthew L Cooper, Karl Staser, et al.
Bone Marrow Transplantation|May 21, 2014
Haploidentical transplantation using G-CSF-mobilized T-cell replete PBSCs and post-transplantation CY after non-myeloablative conditioning is safe and is associated with favorable outcomesP K Bhamidipati, J F DiPersio, K Stokerl-Goldstein, et al.
Bone Marrow Transplantation|July 20, 2004
Supraventricular tachyarrhythmias after hematopoietic stem cell transplantation: incidence, risk factors and outcomesJ D Hidalgo, R Krone, M W Rich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Outcomes of high-dose chemotherapy and autologous stem-cell transplantation in stage IIIB inflammatory breast cancerD Adkins, R Brown, K Trinkaus, et al.
Leukemia|July 6, 2012
The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effectsM A Hurchla, A Garcia-Gomez, M C Hornick, et al.
Leukemia|May 15, 2013
Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 studyA J Jakubowiak, D S Siegel, T Martin, et al.
Cancer Cell|May 26, 2023
Context-dependent activation of STING-interferon signaling by CD11b agonists enhances anti-tumor immunityXiuting Liu, Graham D Hogg, Chong Zuo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 16, 2024
HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal AdenocarcinomaNaomi Yamamoto, Stephanie Dobersch, Ian Loveless, et al.
Pageof 6

Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
Transplant Infectious Disease : an Official Journal of the Transplantation Society|November 19, 2011
Oral valganciclovir versus ganciclovir as delayed pre-emptive therapy for patients after allogeneic hematopoietic stem cell transplant: a pilot trial (04-0274) and review of the literatureJ S Chawla, A Ghobadi, J Mosley, et al.
Bone Marrow Transplantation|July 5, 2001
Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulinH Khoury, A Kashyap, D R Adkins, et al.
Leukemia|April 26, 2018
Baricitinib-induced blockade of interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft-versus-host diseaseJaebok Choi, Matthew L Cooper, Karl Staser, et al.
Bone Marrow Transplantation|May 21, 2014
Haploidentical transplantation using G-CSF-mobilized T-cell replete PBSCs and post-transplantation CY after non-myeloablative conditioning is safe and is associated with favorable outcomesP K Bhamidipati, J F DiPersio, K Stokerl-Goldstein, et al.
Bone Marrow Transplantation|July 20, 2004
Supraventricular tachyarrhythmias after hematopoietic stem cell transplantation: incidence, risk factors and outcomesJ D Hidalgo, R Krone, M W Rich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Outcomes of high-dose chemotherapy and autologous stem-cell transplantation in stage IIIB inflammatory breast cancerD Adkins, R Brown, K Trinkaus, et al.
Leukemia|July 6, 2012
The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effectsM A Hurchla, A Garcia-Gomez, M C Hornick, et al.
Leukemia|May 15, 2013
Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 studyA J Jakubowiak, D S Siegel, T Martin, et al.
Cancer Cell|May 26, 2023
Context-dependent activation of STING-interferon signaling by CD11b agonists enhances anti-tumor immunityXiuting Liu, Graham D Hogg, Chong Zuo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 16, 2024
HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal AdenocarcinomaNaomi Yamamoto, Stephanie Dobersch, Ian Loveless, et al.
Pageof 6